Pavilion Health Today
Supporting healthcare professionals to deliver the best patient care

Trial data reveals Saxenda improves weight loss and cardiometabloic risk factors in patients with diabetes

Saxenda (liraglutide) could benefit patients with prediabetes and obesity to help them achieve weight loss and improve cardiometabolic risk factors, data from the Phase 3 SCALE (Satiety and Clinical Adiposity €“ Liraglutide Evidence) Obesity and Prediabetes trial has revealed.

 Saxenda (liraglutide) could benefit patients with prediabetes and obesity to help them achieve weight loss and improve cardiometabolic risk factors, data from the Phase 3 SCALE (Satiety and Clinical Adiposity – Liraglutide Evidence) Obesity and Prediabetes trial has revealed. The evidence, presented at the first European Obesity Summit (EOS 2016), looked at adults with prediabetes and obesity or who were overweight with comorbidities. These were randomised to receive liraglutide (n=1,505) or placebo (n=749) for 160 weeks, both as an adjunct to a reduced-calorie diet and increased physical activity.  The study found that people treated with liraglutide who lost 5% or

---------------------------

This content is restricted to members of Pavilion Health Today. If you are an existing user, please log in. New users may register for free below.

Existing Users Log In
   
New User Registration
captcha
*Required field

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read more ...

Privacy & Cookies Policy